103 related articles for article (PubMed ID: 29251317)
21. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
22. Combined Treatment with CCI779 and SB203580 Induces Cellular Senescence in Renal Cell Carcinoma Cell Line via p53 Pathway.
Chauhan A; Ojha R; Semwal DK; Mishra SP; Semwal RB
Anticancer Agents Med Chem; 2017 Nov; 17(11):1545-1554. PubMed ID: 28270077
[TBL] [Abstract][Full Text] [Related]
23. Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel.
Chang HR; Chen PN; Yang SF; Sun YS; Wu SW; Hung TW; Lian JD; Chu SC; Hsieh YS
Mol Carcinog; 2011 Oct; 50(10):811-23. PubMed ID: 21574189
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Li H; Jin X; Zhang Z; Xing Y; Kong X
Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
[TBL] [Abstract][Full Text] [Related]
25. Autophagy induction by silibinin positively contributes to its anti-metastatic capacity via AMPK/mTOR pathway in renal cell carcinoma.
Li F; Ma Z; Guan Z; Chen Y; Wu K; Guo P; Wang X; He D; Zeng J
Int J Mol Sci; 2015 Apr; 16(4):8415-29. PubMed ID: 25884331
[TBL] [Abstract][Full Text] [Related]
26. Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma.
Ma Z; Liu W; Zeng J; Zhou J; Guo P; Xie H; Yang Z; Zheng L; Xu S; Wang X; Chang LS; He D; Li L
Oncol Rep; 2015 Nov; 34(5):2461-8. PubMed ID: 26323996
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway.
Liang L; Li L; Zeng J; Gao Y; Chen YL; Wang ZQ; Wang XY; Chang LS; He D
Oncol Rep; 2012 Sep; 28(3):999-1005. PubMed ID: 22736024
[TBL] [Abstract][Full Text] [Related]
28. In vitro anticancer activities of osthole against renal cell carcinoma cells.
Liu L; Mao J; Wang Q; Zhang Z; Wu G; Tang Q; Zhao B; Li L; Li Q
Biomed Pharmacother; 2017 Oct; 94():1020-1027. PubMed ID: 28810525
[TBL] [Abstract][Full Text] [Related]
29. TFE3 regulates renal adenocarcinoma cell proliferation via activation of the mTOR pathway.
Fang Y; Bao W; Rao Q; Wang X; Xia Q; Shen Q; Zhou X; Yao B
Mol Med Rep; 2017 Sep; 16(3):2721-2725. PubMed ID: 28713889
[TBL] [Abstract][Full Text] [Related]
30. Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells.
Pan ST; Qin Y; Zhou ZW; He ZX; Zhang X; Yang T; Yang YX; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1601-26. PubMed ID: 25834400
[TBL] [Abstract][Full Text] [Related]
31. Protein Kinase RNA-Like Endoplasmic Reticulum Kinase-Mediated Bcl-2 Protein Phosphorylation Contributes to Evodiamine-Induced Apoptosis of Human Renal Cell Carcinoma Cells.
Wu WS; Chien CC; Chen YC; Chiu WT
PLoS One; 2016; 11(8):e0160484. PubMed ID: 27483435
[TBL] [Abstract][Full Text] [Related]
32. Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target.
Chen CH; Fong LWR; Yu E; Wu R; Trott JF; Weiss RH
Oncogene; 2017 Jun; 36(25):3588-3598. PubMed ID: 28166200
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma.
Kausch I; Jiang H; Thode B; Doehn C; Krüger S; Jocham D
Eur Urol; 2005 May; 47(5):703-9. PubMed ID: 15826766
[TBL] [Abstract][Full Text] [Related]
34. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
35. Future perspectives for mTOR inhibitors in renal cell cancer treatment.
Czarnecka AM; Kornakiewicz A; Lian F; Szczylik C
Future Oncol; 2015; 11(5):801-17. PubMed ID: 25757683
[TBL] [Abstract][Full Text] [Related]
36. Apoptotic effect of green synthesized gold nanoparticles from
Liu R; Pei Q; Shou T; Zhang W; Hu J; Li W
Int J Nanomedicine; 2019; 14():4091-4103. PubMed ID: 31239669
[No Abstract] [Full Text] [Related]
37. Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.
Wu M; Si S; Li Y; Schoen S; Xiao GQ; Li X; Teh BT; Wu G; Chen J
Oncotarget; 2015 Oct; 6(32):32761-73. PubMed ID: 26418749
[TBL] [Abstract][Full Text] [Related]
38. 8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition.
Kearney AY; Fan YH; Giri U; Saigal B; Gandhi V; Heymach JV; Zurita AJ
PLoS One; 2015; 10(8):e0135962. PubMed ID: 26313261
[TBL] [Abstract][Full Text] [Related]
39. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
[TBL] [Abstract][Full Text] [Related]
40. Anti-proliferative and pro-apoptotic activities of Alpinia oxyphylla on HepG2 cells through ROS-mediated signaling pathway.
Zhang Q; Cui C; Chen CQ; Hu XL; Liu YH; Fan YH; Meng WH; Zhao QC
J Ethnopharmacol; 2015 Jul; 169():99-108. PubMed ID: 25891473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]